Broad Bactericidal Activity of the <i>Myoviridae</i> Bacteriophage Lysins LysAm24, LysECD7, and LysSi3 against Gram-Negative ESKAPE Pathogens

• Main Authors: Nataliia P. Antonova, Daria V. Vasina, Anastasiya M. Lendel, Evgeny V. Usachev, Valentine V. Makarov, Alexander L. Gintsburg, Artem P. Tkachuk, Vladimir A. Gushchin
• Format: Article
• Language: English
• Published: MDPI AG 2019-03-01
• Series: Viruses
• Subjects: bacteriophages; <i>Myoviridae</i>; bacteriophage-derived lytic enzyme; enzybiotics; endolysin; in vitro activity; ESKAPE
• Online Access: https://www.mdpi.com/1999-4915/11/3/284

The extremely rapid spread of multiple-antibiotic resistance among Gram-negative pathogens threatens to move humankind into the so-called &#8220;post-antibiotic era&#8222; in which the most efficient and safe antibiotics will not work. Bacteriophage lysins represent promising alternatives to antibiotics, as they are capable of digesting bacterial cell wall peptidoglycans to promote their osmotic lysis. However, relatively little is known regarding the spectrum of lysin bactericidal activity against Gram-negative bacteria. In this study, we present the results of in vitro activity assays of three putative and newly cloned <i>Myoviridae</i> bacteriophage endolysins (LysAm24, LysECD7, and LysSi3). The chosen proteins represent lysins with diverse domain organization (single-domain vs. two-domain) and different predicted mechanisms of action (lysozyme vs. peptidase). The enzymes were purified, and their properties were characterized. The enzymes were tested against a panel of Gram-negative clinical bacterial isolates comprising all Gram-negative representatives of the ESKAPE group. Despite exhibiting different structural organizations, all of the assayed lysins were shown to be capable of lysing <i>Pseudomonas aeruginosa</i>, <i>Acinetobacter baumannii</i>, <i>Klebsiella pneumoniae</i>, <i>Escherichia coli</i>, and <i>Salmonella typhi</i> strains. Less than 50 &#956;g/mL was enough to eradicate growing cells over more than five orders of magnitude. Thus, LysAm24, LysECD7, and LysSi3 represent promising therapeutic agents for drug development.